Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Usgena

Usgena 45 mg solution for injection Usgena 45 mg solution for injection in pre-filled syringe Usgena 90 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 32

HOS-153992 · Präparat HOS-101078

Paediatric patients 6 years and older with plaque psoriasis The safety of ustekinumab has been studied in two phase 3 studies of paediatric patients with moderate to severe plaque psoriasis. The first study was in 110 patients from 12 to 17 years of age treated for up to 60 weeks and the second study was in 44 patients from 6 to 11 years of age treated for up to 56 weeks. In general, the adverse events reported in these two studies with safety data up to 1 year were similar to those seen in previous studies in adults with plaque psoriasis.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.